Meetings
Conference abstracts
81 public abstracts from 2021 to 2026. Findings are the abstract’s own wording. Level 1 items, where ctDNA or MRD assigned treatment or surveillance, have a coral bar. Slide and poster links, when added, may require an ASCO or ESMO member login.
10 abstracts
- Level 2ESMO Breast Cancer 2026
416O - SMART: On-treatment ctDNA dynamics predicts response and progression in metastatic breast cancer
Pedram Razavi · Abstract 416O · Proffered Paper (oral) · SMART
SlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
- Level 2prognosticASCO Annual Meeting 2025
Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study.
Yoo, Tae-Kyung Robyn · Abstract 3055 · CHiRP · same 83-patient analytic cohort as the 2022 abstract; median follow-up from first sample 4.4 years; 214 plasma samples before known recurrence
RaDaR (tumor-informed, whole-exome-based)
With longer follow-up, all 8/8 patients with ctDNA detected at any timepoint developed distant recurrence (median lead time 1.39 years, range 0.01-4.24). A negative test had a negative predictive value for remaining recurrence-free of 100% at more than 1 year (0/196), 98.4% at more than 2 years (3 events among 185 samples), and 96.6% at more than 3 years (5/147).
- Trial in progressESMO Congress 2025
HEROES: De-escalation of anti-HER2 therapies in HER2-positive metastatic breast cancer with long-term persistent response and undetectable MRD in ctDNA
Benjamin Verret (with Thibault De La Motte Rouge) · Abstract 620TiP · Poster / trial-in-progress · HEROES
Trial in progress
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Trial in progressESMO Congress 2025
The SURVIVE HERoes study: Targeting molecular relapse in breast cancer; trastuzumab deruxtecan versus standard-of-care treatment in ctDNA-positive HER2-positive/HER2-low early breast cancer
Kerstin Pfister · Abstract 464eTiP · Poster / trial-in-progress · SURVIVE HERoes
Trial in progress
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 2prognosticSan Antonio Breast Cancer Symposium 2025
Abstract RF3-05: Tissue-free circulating tumour DNA detection in patients with early triple negative breast cancer from the c-TRAK-TN trial
Cunningham, N. · Abstract RF3-05 · c-TRAK TN · 1,062 timepoints from 159 patients; 1,012 (95.3%) successfully analyzed with the tissue-free assay; 1,005 timepoints compared with ddPCR
Guardant Reveal (tissue-free methylation) compared with digital droplet PCR (1-2 patient-specific variants)
ctDNA was detected by Reveal in 54/159 (34.0%) patients at least once and was associated with relapse (HR 20.62, P<0.0001). Of patients who relapsed by 24 months, 34/38 (89.5%) had prior ctDNA detection. Agreement with ddPCR was 94.5% (950/1005 timepoints). Among detections, 44.8% were first found by the tissue-free assay and 6.9% by ddPCR. Median time from first detection to relapse was 7.9 months with Reveal vs 5.7 months with ddPCR (HR 0.6, P=0.0574).
- Level 2prognosticASCO Annual Meeting 2024
Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
Garcia-Murillas, Isaac · Abstract 1010 · ChemoNEAR · 76 patients with early breast cancer (23 TNBC, 33 HER2-positive, 16 HR-positive, 4 unknown); 598 plasma samples
NeXT Personal (Personalis), tumor-informed whole-genome personalized panels of up to about 1,800 variants
At a median follow-up of 76 months, ctDNA detection was associated with relapse (HR undefined, P<0.0001) and shorter OS (P<0.0001), with a median lead time of 12.5 months (range 1-60). MRD was identified in 10/10 patients who relapsed (median 18.5 PPM at first detection). None of 58 patients who remained ctDNA-undetected relapsed. Of patients undetected at the post-surgical landmark, 31/33 (94%) did not relapse. Forty percent of all detections were below 100 PPM.
- Level 1mixedSan Antonio Breast Cancer Symposium 2024
Abstract GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy
Turner, Nicholas · Abstract GS3-01 · oral · ZEST · 2,746 prescreened; 1,901 with at least one ctDNA result; 147 (8%) ctDNA-positive; 40 randomized (18 niraparib, 22 placebo) before early termination
Signatera (personalized tumor-informed, whole-exome-based)
Enrollment was stopped early because of a low ctDNA-positivity rate (8% of 1,901 tested; 5.2% on the first test) and a high rate of radiographic recurrence already present at first ctDNA positivity (72/147, 49%). Among the 40 randomized patients, median DFS was 11.4 months with niraparib vs 5.4 months with placebo (HR 0.64, 95% CI 0.30-1.39), a comparison the sample size cannot support as a conclusive efficacy result. No new safety signals for niraparib were reported.
- Level 2prognosticASCO Annual Meeting 2022
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).
Lipsyc-Sharf, Marla · Abstract 103 · CHiRP · 103 enrolled; 83 with successful whole-exome sequencing and personalized assays; 219 plasma samples
RaDaR (personalized, tumor-informed; 12-51 variants, median 36)
At a median of 8.4 years from diagnosis to first sample, 8/83 (10%) were MRD-positive at any timepoint and 4/83 (5%) were positive at study entry. All 5 patients with distant metastatic recurrence were MRD-positive, with ctDNA lead times up to 37.6 months. Two of 8 MRD-positive patients had not recurred at latest follow-up.
- Level 2prognosticSan Antonio Breast Cancer Symposium 2022
Abstract PD5-03: PD5-03 Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial
Coakley, Maria · Abstract PD5-03 · poster discussion · c-TRAK TN · Agreement and lead-time comparison on c-TRAK TN samples; exact patient n is given in rates (9 patients RaDaR-only positive, 3 dPCR-only) but a single total n is not restated as a standalone figure in the extracted results beyond the agreement analysis
RaDaR (personalized multi-mutation sequencing) compared with digital PCR mutation tracking
Overall test agreement was 92.7% (95% CI 90.7-94.4%). From a patient-level view, 58.7% were negative on both assays, 32.9% positive on both, and 8.6% discordant (ctDNA detected by RaDaR but not dPCR in 9 patients, and the reverse in 3). Among ctDNA-positive patients, 55.2% were first detected by RaDaR, 5.2% by dPCR, and 39.6% at the same timepoint (P<0.001). Median lead time to relapse was 7.1 months with RaDaR vs 5.7 months with dPCR.
- Level 1mixedSan Antonio Breast Cancer Symposium 2021
Abstract GS3-06: Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer
Turner, Nicholas · Abstract GS3-06 · oral · c-TRAK TN · 208 registered; 171 with trackable mutations; 161 entered ctDNA surveillance
digital PCR mutation tracking (1-2 patient-specific variants), as described in the companion full paper and later assay-comparison abstracts from the same trial
The 12-month ctDNA detection rate was 27.3% (44/161). Seven patients relapsed without prior ctDNA detection. Of patients allocated to pembrolizumab, 23/32 (72%) already had metastatic disease on staging at the time of ctDNA detection. Only 5 patients started pembrolizumab; none achieved sustained ctDNA clearance, and 4 had recurred at analysis. In the observation group, median time to recurrence was 4.1 months. The therapeutic activity endpoint could not be assessed.